You are here: Home » PTI Stories » National » News
Business Standard

Glenmark expands its oncology franchise in India with launch of Helsinn's Akynzeo

Press Trust of India  |  New Delhi 

and Swiss pharma group Helsinn today announced the launch of Akynzeo, a fixed dose combination drug for prevention of and vomiting, in

The drug has been launched in the Indian market under an exclusive licensing agreement, the companies said in a joint statement.

The product has been developed by Helsinn and Glenmark has exclusive marketing rights for it in and Nepal, it added.

Helsinn is focused on helping people with get the best out of every day and is pleased to be expanding its availability, said

"is a single-dose oral capsule for each cycle that covers both the acute and delayed phase of and (CINV)," Glenmark President Formulations, and Africa Sujesh Vasudevan said.

The product is already being marketed in the EU, the US and several other leading markets of the world, the statement said.

Shares of Glenmark were trading at Rs 582.50 per scrip on BSE, up 0.09 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, July 10 2018. 14:35 IST